Podcasts about ADC

Are you looking to save time, make money, and start winning with less risk? Then head to https://www.ovtlyr.com.The stock market is sending some serious warning signs right now. If you've been trying to buy the dip, dollar cost averaging your way down, or chasing every bounce, you're probably feeling the pain. This video breaks down why sitting on the sidelines can sometimes be the smartest trade, how to recognize trend shifts before they smack you in the face, and where the real opportunities might show up next.We dive deep into the importance of having a rules-based plan, why consistency and discipline matter more than hype, and how the OVTLYR signals are pointing to some major shifts under the surface. From market breadth and fear vs. greed readings to sector breakdowns and individual stock setups, this is your chance to see exactly what's happening behind the curtain.One of the big takeaways here: you don't have to catch every move. Winners average winners, losers average losers. If the market is running hot with greed, that's often when a snapback is lurking around the corner. Understanding when to sit out and when to strike is what separates disciplined traders from gamblers.Inside this session, we cover:➡️ Why dollar cost averaging in a downtrend can turn into a costly mistake➡️ The power of “sit out” trades and why cash is sometimes the best position➡️ Key lessons from OVTLYR's nine-signal system and how fewer signals can actually lead to more trades➡️ What market breadth, sector rotations, and fear/greed indicators are flashing right now➡️ Stock-specific breakdowns, including Nvidia ahead of earnings, sector leaders, and a few surprising setups in utilities, staples, and communicationsYou'll also see how order blocks reveal where buyers keep getting trapped, why some charts scream “strong buy” while others are flashing “GTFO,” and how expected moves in the options chain can set realistic expectations for volatility. Whether it's Nvidia, Palantir, Duke Energy, or lesser-known tickers like ADC, BZ, and GFL, the same rules apply: risk comes first, profits follow.This isn't about gambling on earnings or hoping for miracle rebounds. It's about protecting your capital, waiting for high-probability setups, and trading with confidence when the odds are finally stacked in your favor. If you've ever been burned holding through a big report, or found yourself stuck in a sideways chop, this breakdown is going to help you see the market differently.Remember, the market doesn't care about opinions—it only cares about price, trend, and momentum. Learn how to read those signals, avoid common traps, and put yourself in a position to win more and risk less.If you're serious about trading smarter, stick around until the end. There's money to be made, but only if you follow your plan, stay disciplined, and keep risk management front and center.Gain instant access to the AI-powered tools and behavioral insights top traders use to spot big moves before the crowd. Start trading smarter today

Antibody-drug conjugates (ADCs) are a relatively new type of medicine for breast cancer. Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) and Dato-DXd (brand name: Datroway) are two ADCs used to treat breast cancer. Dr Benjamin Schrank and colleagues have developed a new type of ADC that combines an antibody with a toxin — called an antibody-toxin conjugate — that teaches the immune system to recognize and attack cancer cells. Listen to the episode to hear Dr. Schrank explain: the antibody and the toxin component of the medicine how the new medicine works possible side effects next steps for the research Episode image photo credit: The University of Texas MD Anderson Cancer Center

This week on Dividend Talk, Derek is joined by Jeremy from Dividend Stockpile to explore some of the biggest Megatrends shaping our investing future. We cover the opportunities and risks in infrastructure, clean energy, technology, and healthcare, and how dividend investors can position themselves for the next decade and beyond.You'll hear about recent dividend news from Interface (TILE) and Agree Realty (ADC), how US and European infrastructure approaches differ, why utilities like Iberdrola (IBE.MC) and Enel (ENEL.MI) stand out, and how tech giants Meta (META), Alphabet (GOOG), and Microsoft (MSFT) fit into the AI megatrend. We also look into healthcare innovation, options income strategies, and favourite finance content creators.Tickers Mentioned: TILE, ADC, O, BAM, BIP, NEE, DUK, ED, IBE.MC, ENEL.MI, ABB, DG.PA, META, GOOG, MSFT, GE, CWEN, ASML.AS, SAP, MDT, MRK, ABBV, NVO, LLY, ROG.SW, SNY, SYK, ABT, BDX, RMD, STRCChapters:00:00 – Introduction & Guest Welcome02:52 – Company News: Interface & Dividend Increases05:41 – Agree Realty & REIT Quality08:43 – Understanding Megatrends11:51 – Infrastructure as a Megatrend29:06 – Clean Energy Transition39:31 – The Rise of Technology & AI46:51 – Healthcare Opportunities01:04:06 – Options Income Strategies & High Yield Ideas01:20:06 – Favorite Finance Content Creators & Closing RemarksGet a free sample of our premium dividend newsletter! Stay ahead of the market with in-depth stock analysis here: https://dividendtalk.eu/download-your-free-samples/ Stay Updated:Twitter - @DividendTalk_Twitter - @European_DGIJoin our Facebook Community - Dividend Talk Facebook GroupJoin our Discord group - https://discord.gg/nJyt9KWAB5

This week on EYE ON NPI we're featuring some open source hardware from one of our favorite hardware manufacturers! It's the Arduino Nano R4 System on Module (https://www.digikey.com/en/product-highlight/a/arduino/nano-r4) a miniaturized version of the Arduino UNO R4 and Minima (https://blog.adafruit.com/2023/07/27/eye-on-npi-arduino-uno-r4-minima-and-uno-r4-wifi-boards-digikey-arduino-digikey-adafruit/) versions we covered on EYE ON NPI about two years ago! taking a cue from popular 'castellated single side' PCB proto boards on the market, the Nano comes in two options, one with headers (https://www.digikey.com/en/products/detail/arduino/ABX00143/26766495) for easy installation into existing Arduino Nano expansion kits or breadboards, and one with reflowable castellations (https://www.digikey.com/en/products/detail/arduino/ABX00142/26766490) The Arduino Nano (https://www.digikey.com/en/products/detail/arduino/A000005/2638989) is second only to the UNO as the definitive Arduino board that 'everyone got started with'. Many folks would start with the chunky UNO and then migrate to the Nano to get something that plugs into a breadboard for compact assembly. With a USB connector on one end, button and LEDs and programming header on the top, this board powered tens of thousands of builds. So it's not surprising that Arduino iterated on this design with a wide variety of chips like the RP2040 (https://www.digikey.com/en/products/detail/arduino/ABX00052/14123941) and ESP32 (https://www.digikey.com/en/products/detail/arduino/ABX00092/21219771) The latest generation is the Renesas RA4M1 series - which updates the original ATmega328 8-bit microcontroller to a beefy Cortex M4 with FPU. You get 48MHz clock, 256KB of Flash, 32KB of SRAM, ADC, DAC, CAN, captouch and other extras. The FPU in particular makes it a nice upgrade to the cortex M0/M0+. The best part is that with the 5V logic support of the R7FA4M1AB3CFM (https://www.digikey.com/en/products/detail/renesas-electronics-corporation/R7FA4M1AB3CFM-AA0/10447195), it makes for a great drop-in replacement when a 3V logic chip like the RP2040/ESP32 won't work as well. Plus you get lots of nice linear ADCs, the RP2040 only has 4 and the ESP32's are non-linear and sometimes don't work when WiFi is active. We also love that they added a Qwiic (https://www.sparkfun.com/qwiic) connector on the end! We use this for all our Stemma QT sensors, and between the many companies that have joined in the ecosystem there are easily a thousand different ons/displays/accessories that can plug in directly for instant expansion. If you want to get the latest Nano from the manufacturer of genuine Arduino boards, DigiKey is a authentic distributor and has tons of the Arduino Nano R4 (https://www.digikey.com/short/3brjrnjp) in stock right now for (https://www.digikey.com/en/products/detail/arduino/ASX00061/26744081) immediate shipment! Pick from the castellated flat or soldered-header variety, and don't forget to also grab some Arduino Nano accessories to get your design prototyped fast. Order today and your Nano will fly out of the DigiKey warehouse and arrive at your doorstep by tomorrow morning.

Cet épisode est présenté par Squarespace.La plateforme tout-en-un pour créer un site élégant et professionnel, même sans compétences techniques.Templates au design impeccable, outils puissants, et un assistant IA qui simplifie tout.Essayez gratuitement 14 jours et profitez de -10 % avec le code BOLD sur squarespace.com/BOLD.

The Making of KOLs: The New Chemist Podcast's Global Journey in Science, Pharma, and Education: Interview with Mohan Uttarwar, CEO & Co-Founder of 1Cell.Ai---In this episode , we sit down with Mohan Uttarwar, CEO & Co-Founder of 1Cell.Ai, to explore how AI-driven single-cell analytics are revolutionizing precision oncology. Discover how the OncoIncytes platform merges ctDNA, live CTCs, single-cell RNA and proteomics for a real-time, multimodal tumor profile—and learn how these insights are sharpening patient selection, accelerating ADC trials, and delivering earlier, more accurate measures of therapeutic response. Mohan also shares his playbook for building a capital-efficient biotech across Silicon Valley and India, the emerging trends set to reshape drug development, and practical advice for chemists, data scientists, and founders looking to break into the field. Tune in this August for a deep dive into the future of cancer research and drug discovery.--Please note: The views of this podcast represent those of my guest(s) and I.Music citation: Open source

“Colorectal cancer treatment is not just about eliminating a disease. It's about preserving life quality and empowering patients through every phase. So I think nurses are really at the forefront that we can do that in the oncology nursing space. So from early detection to survivorship, the journey is deeply personal. Precision medicine, compassionate care, and informed decision-making are reshaping outcomes. Treatment's just not about protocols. It's about people,” ONS member Kris Mathey, DNP, APRN-CNP, AOCNP®, gastrointestinal medical oncology nurse practitioner at The James Cancer Hospital of The Ohio State University Wexner Medical Center in Columbus, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about colorectal cancer treatment.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 1.0 contact hour of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 1, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the treatment of colorectal cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 370: Colorectal Cancer Screening, Early Detection, and Disparities Episode 153: Metastatic Colorectal Cancer Has More Treatment Options Than Ever Before ONS Voice articles: Colorectal Cancer Prevention, Screening, Treatment, and Survivorship Recommendations Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) How Liquid Biopsies Are Used in Cancer Treatment Selection Oncology Drug Reference Sheet: 5-Fluorouracil Oncology Drug Reference Sheet: Oxaliplatin What Is a Liquid Biopsy? Clinical Journal of Oncology Nursing article: Colorectal Cancer in Young Adults: Considerations for Oncology Nurses Oncology Nursing Forum article: Neurotoxic Side Effects Early in the Oxaliplatin Treatment Period in Patients With Colorectal Cancer ONS Colorectal Cancer Learning Library ONS Biomarker Database (filtered by colorectal cancer) ONS Peripheral Neuropathy Symptom Interventions American Cancer Society colorectal cancer resources CancerCare Colorectal Cancer Alliance Colorectal Cancer Resource and Action Network Fight Colorectal Cancer National Comprehensive Cancer Network To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Colorectal cancer has several different types, but there is one that dominates the landscape, and that is adenocarcinoma. So I think most of us have heard that. It's fairly common, and it accounts for about 95% of all colorectal cancers. It begins in the glandular cells lining the colon or rectum and often develops from polyps, in particular adenomatous polyps.” TS 1:41 “One of the biomarkers that we'll most commonly hear about is KRAS or NRAS mutations. This indicates tumor genetics, and these mutations suggest resistance to our EGFR inhibitors such as cetuximab. BRAF mutation or V600E is a more aggressive tumor subtype, and those may respond to our BRAF targeted therapy. … And then our MSI-high or MMR-deficient—microsatellite instability or mismatch repair deficiency—that really predicts an immunotherapy response and may indicate Lynch syndrome, which is a huge genetic component that takes a whole other level of counseling and genetic testing with our patients as well.” TS 6:02 “Polypectomy or a local excision—that removes our small tumors or polyps during that colonoscopy. And that's what's used for those stage 0 or early stage I cancers. A colectomy removes part or all of the colon. This may be open or laparoscopic. It can include a hemicolectomy, a segmental resection, or a total colectomy, so where you take out the entire part of the colon. A proctectomy removes part or all of the rectum. This may include a low anterior resection, also known as an LAR … or an abdominal perineal resection, which is an APR. … Colostomy or ileostomy—that diverts the stool to an external bag via stoma. Sometimes this is temporary or permanent depending on the type of surgery.” TS 14:11 “We'll have our patients say, ‘Hey, I want immunotherapy therapy. I see commercials on it that it works so well.' We have to make sure that these patients are good candidates for it, also that we're treating them adequately. We need to make sure that they have those biomarkers, so as I mentioned, the MSI-high or MMR tumors. Our MSS-stable tumors—they may benefit from newer combinations or clinical trials. Metastatic disease—immunotherapy may be used alone or with other treatments. And then in the neoadjuvant setting, some trials are really showing promising results using immunotherapy prior to surgery.” TS 25:38 “Antibody-drug conjugates are really an exciting frontier in all cancer treatments as well as colorectal cancer treatment. This is used mainly for patients with advanced or treatment-resistant disease, and these therapies combine the targeted power of monoclonal antibodies with the cell-killing ability of potent chemotherapy agents. They're still on the horizon for the most part in colorectal cancer. However, there is only one approved antibody-drug conjugate, or ADC, at this time, and that's trastuzumab deruxtecan, or Enhertu. That's approved for any solid tumor, such as colorectal cancer with HER2 IHC 3+. So again, looking back at that pathology in those markers, making sure that you have that HER2 mutation and that IHC.” TS 35:00 “There are a few myths going around about colorectal cancer treatment that can lead to confusion or even delayed care. One myth is only older men get colorectal cancer. As you heard me talk in my previous podcast on screening, unfortunately, this isn't necessarily true. Colorectal cancer affects both men and women and our cases in the younger population are rising. So our screening guidelines have changed to age 45 because we are seeing it in the younger population.” TS 45:54

In this special episode of Dividend Talk, we tackle one of the most frustrating topics for European investors: dividend withholding tax. Our guest is Thomas Rappold, founder of Divizend.com, a platform built to automate and simplify dividend tax reclaims for retail investors. Thomas shares how his own investing struggles led him to build the company, and how Divizend is helping thousands of investors recover lost income from foreign dividends.We discuss:​What dividend withholding tax is (and why it's such a headache)​Why most investors miss out on reclaiming what's rightfully theirs​The upcoming EU-Faster regulation and digital tax residency certificates​The role of brokers, the EU Commission, and what's changing by 2028​Practical steps for reclaiming your foreign dividend taxes​Why dividend investors need to push for change and how Divizend is giving us a voice​Thomas also shares his unique investing mindset (yes, he owns both Palantir and Lindt!) and replaces a stock in our Dividend Growth Community Portfolio.

Welcome back to The Dive Driven by Kia! Kobe, Azael and Meteos look ahead to 4 more years of T1 Faker before breaking down 4 opening week sweeps in the LTA North. After the break, we look ahead to this weekend's matchups as chosen by the teams themselves. Finally, Patch 25.15 is live! The crew discusses Braum nerfs, the state of ADC and more.Timestamps:0:00 - Intro & Faker Re-signs to T18:15 - Travis Gafford Steps Away12:37 - LTA Split 3 Format17:13 - Team Liquid vs 100 Thieves Review34:23 - Shopify Rebellion vs Dignitas Review45:21 - Cloud9 vs Lyon Review53:51 - FlyQuest vs Disguised Review1:01:56 - Week 2 Matches Preview1:11:18 - Patch 25.151:19:48 - ADC & Balance Debate 

In this episode, listen to Laura M. Spring, MD; and Shipra Gandhi, MD, MS, share their takeaways from a large educational program on available and emerging first-line treatment options for patients with HER2-positive mBC:Emerging new data from the phase IIII DESTINY-Breast09 trial of first-line treatment with trastuzumab deruxtecan ± pertuzumab vs THP for advanced HER2-positive breast cancerInteractive decision support tool with recommendations from 5 experts for the treatment of HER2-positive breast cancerOutcomes data from a live webinar on applying the latest data for first-line management of HER2-positive mBC, including analyzing the latest clinical results and developing tailored interventions to address challenges with novel ADCs Program faculty:Laura M. Spring, MDBreast Medical OncologistMass General Hospital Cancer CenterHarvard Medical SchoolBoston, Massachusetts Shipra Gandhi, MD, MSAssociate ProfessorDirector, Breast Translational ResearchGlenn Family Breast CenterWinship Cancer Institute of Emory UniversityAtlanta, GeorgiaResources:To access the interactive patient cases associated with this podcast discussion, please visit the program page, to access a recording from a live webinar, and an interactive decision support tool on this topic.

Welcome back to another episode of The Dive Driven by Kia. Champion designer Riot Yelough joins Kobe and Meteos to give some behind-the-scenes intel on the new ADC champ Yunara. Kobe pitches us on his Yunara build (Hullbreaker, Hexplate, Hurricane) and we go over expectations for Yunara in pro play. Will we see Yunara on the LTA stage this weekend? Plus, we break down Patch 25.14, 100 Thieves' last dance, LTA North roster changes and power rankings for Split 3.Finally, make sure to grab tickets for LTA Split 3! Tickets are still available for Opening Week and throughout the entire split, including the LTA Championship in Texas. This Saturday at the Riot Games Arena in LA enjoy a Spirit Blossom themed Opening Day tailgate after the games where you can get a free Spirit Blossom Teemo skin, win prizes, buy some merch (including the exclusive LTA Poro), meet the teams, enjoy free food and more!Purchase your tickets for LTA's Split 3 here: https://www.tixr.com/groups/ltanorth/events/2025-lta-north-split-3-mastercard-opening-week-day-1-150643And get your tickets to the LTA Championship here: https://www.ticketmaster.com/league-of-legends-tickets/artist/2144001Timestamps:0:00 - Introduction with Yunara's Designer Riot Yelough4:54 - Initial Reactions with Yunara's Launch13:23 - Yunara's Itemization22:57 - Thoughts on Yunara in Pro Play33:38 - Evolution of Skill Expression37:57 - Favorite Moments from MSI41:50 - Fantasy is Back42:58 - Patch 25.1455:23 - 100T's Exit from the LTA1:04:53 - LTA Roster Changes1:21:29 - Power Rankings

In this episode, CancerNetwork® spoke with breast oncologists Heather McArthur, MD; Erika Hamilton, MD; Hope Rugo, MD; and Paolo Tarantino, MD, PhD, about advances in breast cancer. These developments included recent drug approvals and ongoing research for therapeutic approaches, particularly in the areas of antibody-drug conjugates (ADCs) and CDK4/6 inhibitors, based on presentations they gave at the 25th Annual International Congress on the Future of Breast Cancer (IBC) East in New York City. Initially, McArthur, Komen Distinguished Chair in Clinical Breast Cancer Research at the Harold C. Simmons Comprehensive Cancer Center, discussed immunotherapy use in high-risk triple-negative and HER2-positive disease, the evolving role of adjuvant CDK4/6 inhibition in HER2-negative breast cancer, and potentially transformative advancements in early breast cancer treatment.  She highlighted the FDA approval for pembrolizumab (Keytruda) in early-stage triple-negative breast cancer, promising clinical trials in estrogen receptor (ER)–positive high-risk early-stage breast cancer, and data from an investigator-initiated trial to treat HER2-positive disease. Additionally, she highlighted an 8.5% improvement in pathological complete response with pembrolizumab added to immunotherapy in the phase 3 KEYNOTE-756 trial (NCT03725059), adding that a further event-free survival benefit may complicate the landscape for CDK4/6 inhibition based on lung and liver toxicities associated with the coadministration of these inhibitors with immunotherapy.1 McArthur expressed further excitement for ADC-based combinations for triple-negative disease, as well as in the high-risk residual disease setting. In addition, she highlighted potential advancements in de-escalation strategies and further considerations for ADCs in the HER2-positive and hormone receptor (HR)–positive spaces. Then, Hamilton, director of Breast Cancer and Gynecologic Cancer Research at the Sarah Cannon Research Institute, highlighted emerging therapies for early breast cancer, as well as her use of datopotamab deruxtecan-dlnk (dato-DXd; Datroway) and fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) given their recent approvals in various breast cancer subtypes. She also touched upon challenges with respect to the implementation of new therapies for early breast cancer into clinical practice. She initially highlighted new data from the phase 3 VERITAC-2 trial (NCT05654623) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.2 Specifically, findings showed that vepdegestrant, an oral proteolysis-targeting chimera (PROTAC), exhibited an efficacy advantage over fulvestrant (Faslodex) in patients with ESR1-mutant ER-positive, HER2-negative advanced or metastatic disease. Moreover, she highlighted data from the phase 3 DESTINY-Breast09 (NCT04784715) of T-DXd in various combinations for patients with HER2-positive metastatic breast cancer.3 Hamilton further highlighted her implementation of T-DXd into clinical practice, citing her use of the agent in patients with metastatic disease, including those with HER2-low and HER2-ultralow breast cancer. She further differentiated dato-DXd from T-DXd, suggesting that they were different classes of drugs due to their different targets: TROP2 vs HER2. She concluded by highlighting an unmet need regarding sustained benefit from endocrine therapy in HR-positive disease, as well as for ADC sequencing and mechanisms of resistance. Afterward, Rugo, division chief of Breast Medical Oncology, Women's Cancer Program Director, and professor in the Department of Medical Oncology and Therapeutics Research at City of Hope, discussed efficacy and safety considerations for CDK4/6 inhibitors in early breast cancer treatment. Specifically, she highlighted their high tolerability despite adverse effects and costs associated with their use. Rugo further touched upon a reduction of recurrence rates associated with CDK4/6 inhibition, although longer-term follow-up data were warranted to optimize the duration of therapy and elucidate survival outcomes. Finally, Tarantino, a research fellow at the Dana-Farber Institute, concluded by discussing sequencing strategies for ADCs, as well as which breast cancer settings or patient populations will experience the greatest impact with this treatment modality. Tarantino discussed his use of the “sandwich strategy,” where he switches the mechanism of action of treatment after using a TOPO1 ADC. Furthermore, Tarantino highlighted data from the DESTINY-Breast09 and phase 3 ASCENT-04 (NCT06100874) trials, which displayed the enhanced efficacy of 2 ADC combination therapies.4 He concluded by discussing future considerations for combining multiple ADCs. References 1. Cardoso F, O'Shaughnessy J, Liu Z, et al. Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial. Nat Med. 2025;31(2):442-448. doi:10.1038/s41591-024-03415-7 2. Hamilton E, De Laurentiis M, Jhaveri K, et al. Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: results of the global, randomized, phase 3 VERITAC-2 study. J Clin Oncol. 2025;43(suppl 17):LBA1000. doi:10.1200/JCO.2025.43.17_suppl.LBA1000 3. Tolaney S, Jiang Z, Zhang Q, et al. Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): interim results from DESTINY-Breast09. J Clin Oncol. 2025;43(suppl 17):LBA1008. 4. Tolaney SM, de Azambuja E, Kalinsky K, et al. Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. J Clin Oncol. 2025;43(suppl 17):LBA109. doi:10.1200/JCO.2025.43.17_suppl.LBA109

The People's Democratic Party (PDP) has been making headlines, not for electoral victories, but for quietly tolerating internal betrayal. Despite members openly supporting rival parties like APC, LP, SDP, and now ADC, the party has taken little or no disciplinary action. In this episode of Nigeria Daily, we ask: is this strategic silence, political weakness, or a total collapse of party discipline?

ADC Talks: otto dialoghi sul mBCIl carcinoma mammario metastatico ha rappresentato il terreno di prova per uno dei filoni di ricerca più innovativi dell'attuale oncologia medica, quello degli Antibody-Drug Conjugates (ADC).Mentre le sperimentazioni proseguono alla scoperta delle possibili applicazioni in altri ambiti di patologia, la storia continua, ampliando ulteriormente la portata di quella che gli oncologi non stentano a definire una “rivoluzione”.In attesa delle ulteriori novità che si intravedono all'orizzonte, DrTalk Oncology e OncoInfo fanno il punto sul tema degli ADC nei tumori mammari, con un podcast in otto puntate interamente dedicato al tema. Matteo Lambertini, nostro ospite d'onore, farà da guida in questo viaggio, accogliendo alcune tra le voci più autorevoli nell'ambito del carcinoma della mammella, e stimolando il confronto sui più importanti aspetti di questo caleidoscopico scenario, sia sul fronte della letteratura che su quello della pratica clinica.Seguici sui nostri socialInstagram (@drtalk_it)YouTube (DrTalk_it)

This week's EYE ON NPI is

ADC Talks: otto dialoghi sul mBCIl carcinoma mammario metastatico ha rappresentato il terreno di prova per uno dei filoni di ricerca più innovativi dell'attuale oncologia medica, quello degli Antibody-Drug Conjugates (ADC).Mentre le sperimentazioni proseguono alla scoperta delle possibili applicazioni in altri ambiti di patologia, la storia continua, ampliando ulteriormente la portata di quella che gli oncologi non stentano a definire una “rivoluzione”.In attesa delle ulteriori novità che si intravedono all'orizzonte, DrTalk Oncology e OncoInfo fanno il punto sul tema degli ADC nei tumori mammari, con un podcast in otto puntate interamente dedicato al tema. Matteo Lambertini, nostro ospite d'onore, farà da guida in questo viaggio, accogliendo alcune tra le voci più autorevoli nell'ambito del carcinoma della mammella, e stimolando il confronto sui più importanti aspetti di questo caleidoscopico scenario, sia sul fronte della letteratura che su quello della pratica clinica.Seguici sui nostri socialInstagram (@drtalk_it)YouTube (DrTalk_it)

The boys discuss the ADC role, League Trivia, MSI, and more on episode 698 of Leaguecast! Email us - mail@leaguecastpodcast.com   Support us - https://www.patreon.com/leaguecast  Tweet us - https://twitter.com/leaguecast   Facebook - https://www.facebook.com/Leaguecast/   Join Our Discord - https://discord.gg/leaguecast  Visit our Website - https://leaguecastpodcast.com/

Masu sauraro wasu kenan daga cikin labarun lamuran da suka wakana a mako mai ƙarewa da shirin Mu Zagaya Duniya ya waiwaya ƙawancen ƴan adawa a Najeriya ya zaɓi  ADC a matsayin jam'iyyar da za su yi haɗaka ƙarkashinta a ƙoƙarinsu na kawo ƙarshen mulkin jam'iyyar APC a 2027.Baya ga rahoto kan wannan haɗewa za a ji tsokacin masana kan wannan yunƙuri. 

Across Nigeria, growing frustration over inflation, insecurity, and unemployment has sparked fresh political interest. In response, opposition parties have formed a new coalition under the African Democratic Congress (ADC) ahead of the 2027 elections, promising real change.But with memories of the 2014 APC coalition still fresh, many Nigerians are asking: is this the solution they've been waiting for, or just another power shuffle?Join us in this episode of Nigeria Daily to find out.

A planned unveiling of the ADC-led opposition coalition was abruptly cancelled by a Hotel in Abuja, just hours before the event. While the hotel said it acted due to “internal compliance,” coalition leaders believe political pressure—especially from the APC—was behind it.So what really happened? And what does this mean for democracy ahead of 2027?This is what we are going to explore in today's episode of Nigeria Daily.#APC #ADC #Nigeria #Election #2027 #Abuja #Tinubu #Atiku #PeterObi #El-rufai

Drs. Yuan and Callahan discuss data presented at ASCO 2025 about DESTINY-Breast06, SHR-A1811, and TQB2101, along with real-world data on rechallenging patients with T-DXd post grade 1 ILD.

Editor-in-Chief of the Archives of Disease in Childhood, Dr. Nick Brown, and Senior Editor of ADC, Dr. Rachel Agbeko bring you the monthly Atoms - the highlights of the July 2025 issue. Read it on the Archives of Disease in Childhood website: https://adc.bmj.com/content/110/7/i      Please listen to our regular podcasts and subscribe in Apple Podcasts, Google Podcasts, Stitcher and Spotify to get episodes automatically downloaded to your phone and computer. And if you enjoy the podcast, please leave us a review at https://podcasts.apple.com/gb/podcast/adc-podcast/id333278832

In this episode, hear Allison Butts, PharmD, BCOP and Danielle Roman, PharmD, BCOP, share their insights on the best practices for incorporating antibody–drug conjugates (ADCs) into clinical practice including:An overview of ADC structure and mechanism of actionA topline review of data supporting the current FDA-approved indications for ADCs targeting HER2 and TROP-2 across multiple tumor typesAn in-depth look at common and serious adverse events with each approved ADC along with an overview of management strategiesEditor's note: On June 23, 2025, the FDA granted accelerated approval for a new indication for datopotamab deruxtecan, one of the antibody drug conjugates discussed in this podcast. Datopotamab deruxtecan is now also approved for adults with locally advanced or metastatic EGFR-mutated NSCLC who have received previous EGFR-targeted therapy and platinum-based chemotherapy. Program faculty:Allison Butts, PharmD, BCOPPharmacist Manager, OncologyClinical Pharmacist, Breast OncologyUK HealthCareMarkey Cancer CenterLexington, KentuckyDanielle Roman, PharmD, BCOPManager, Oncology Clinical Pharmacy ServicesAllegheny Health NetworkPittsburgh, PennsylvaniaProgram page:https://bit.ly/4lr7cT6

NetScaler ADC and NetScaler Gateway Security Bulletin for CVE-2025-6543 Citrix patched a memory overflow vulnerability leading to unintended control flow and denial of service. https://support.citrix.com/support-home/kbsearch/article?articleNumber=CTX694788 Remote code execution in CentOS Web Panel - CVE-2025-48703 An arbitrary file upload vulnerability in the user (not admin) part of Web Panel can be used to execute arbitrary code https://fenrisk.com/rce-centos-webpanel Gogs Arbitrary File Deletion Vulnerability Due to the insufficient patch for the CVE-2024-39931, it's still possible to delete files under the .git directory and achieve remote command execution. https://github.com/gogs/gogs/security/advisories/GHSA-wj44-9vcg-wjq7 Let s Encrypt Will Soon Issue IP Address-Based Certs Let s Encrypt is almost ready to issue certificates for IP address SANs from Let's Encrypt's production environment. They'll only be available under the short-lived profile (which has a 6-day validity period), and that profile will remain allowlist-only for a while. https://community.letsencrypt.org/t/getting-ready-to-issue-ip-address-certificates/238777

Antibody drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, like many of its peers, has embraced the trend head-on. In this week’s episode of "The Top Line," Fierce Pharma’s Zoey Becker speaks with Daejin Abidoye, M.D., AbbVie’s vice president and therapeutic area head for solid tumor oncology. They discuss the company’s evolution, trends from this year’s American Society of Clinical Oncology meeting and what’s ahead for ADCs in oncology. AbbVie, a newer player in the ADC space, recently earned FDA approval for Emrelis in adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have previously received systemic therapy. With a robust pipeline of ADCs in development, Abidoye envisions a bright future for the class—one that could herald “a new era” of cancer treatment beyond traditional chemotherapy. To learn more about the topics in this episode: AbbVie advances solid tumor agenda with FDA nod for lung cancer ADC Emrelis AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field Replacing chemotherapy with ADCs? AbbVie rebuilds next-gen assets after Rova-T flop See omnystudio.com/listener for privacy information.

This week at the desk, we worked on getting more small hardware boards done. We revised our 1.5" transparent OLED breakout (oops, pins were swapped), designed breakouts for sensors like the AS5600 (https://www.digikey.com/en/products/detail/ams-osram-usa-inc/AS5600-ASOM/8250257) and STHS34PF80 (https://www.digikey.com/en/products/detail/stmicroelectronics/STHS34PF80/13187390), and updated the NAU7802 (https://www.digikey.com/en/products/detail/nuvoton-technology-corporation-of-america/NAU7802SGI/4929384) to have both ADC ports available. We're also working on another stepper motor driver, since the TMC2209 breakout (https://www.adafruit.com/product/6121) was a big hit. We wrapped and sent out the Triple-output Active Shifting RGB Matrix Bonnet (https://blog.adafruit.com/2025/02/28/triple-matrix-bonnet-makes-big-bright-displays/). Then we finally had a little time to get back into bigger projects, like Fruit Jam, which we re-picked-up! This week we focused on implementing the ESP32-C6 Wi-Fi co-processor, which needed a bit of rework, but now we've got rev C prototype PCBs on the way. ----------------------------------------- Visit the Adafruit shop online - http://www.adafruit.com LIVE CHAT IS HERE! http://adafru.it/discord Subscribe to Adafruit on YouTube: http://adafru.it/subscribe New tutorials on the Adafruit Learning System: http://learn.adafruit.com/ -----------------------------------------

This week at the desk, we worked on getting more small hardware boards done. We revised our 1.5" transparent OLED breakout (oops, pins were swapped), designed breakouts for sensors like the AS5600 (https://www.digikey.com/en/products/detail/ams-osram-usa-inc/AS5600-ASOM/8250257) and STHS34PF80 (https://www.digikey.com/en/products/detail/stmicroelectronics/STHS34PF80/13187390), and updated the NAU7802 (https://www.digikey.com/en/products/detail/nuvoton-technology-corporation-of-america/NAU7802SGI/4929384) to have both ADC ports available. We're also working on another stepper motor driver, since the TMC2209 breakout (https://www.adafruit.com/product/6121) was a big hit. We wrapped and sent out the Triple-output Active Shifting RGB Matrix Bonnet (https://blog.adafruit.com/2025/02/28/triple-matrix-bonnet-makes-big-bright-displays/). Then we finally had a little time to get back into bigger projects, like Fruit Jam, which we re-picked-up! This week we focused on implementing the ESP32-C6 Wi-Fi co-processor, which needed a bit of rework, but now we've got rev C prototype PCBs on the way. ----------------------------------------- Visit the Adafruit shop online - http://www.adafruit.com LIVE CHAT IS HERE! http://adafru.it/discord Subscribe to Adafruit on YouTube: http://adafru.it/subscribe New tutorials on the Adafruit Learning System: http://learn.adafruit.com/ -----------------------------------------

Exploring the emerging field of grief therapy with Dr. Tom Nehmy, a clinical psychologist specializing in Induced After Death Communication (IADC). We dive into how IADC uses EMDR techniques to help clients process sadness and facilitate after death communications, offering new pathways for healing. Tom shares his personal journey, the clinical research supporting IADC, and what differentiates genuine after death communications from imagination. We also touch on the role of intuition in therapy, the impact of spiritual experiences on grief recovery, and the growing need for spiritually-informed clinical practices. Head to the podcast page for episode notes, Dr. Nehmy's resources, and further reading on IADC. 0:00 - Amy introduces Dr. Tom and IADC therapy 2:34 - Tom Niemi's personal journey with grieving and after death communications 10:41 - Amy and Tom explain EMDR and its use in trauma therapy 18:20 - Dr. Nehmy details the IADC therapy process and origins 23:07 - What qualifies as an after death communication (ADC) 34:06 - Research and effectiveness of IADC for grief 45:45 - Acceptance, commonalities with NDEs DR. TOM NEHMY https://www.tomnehmy.com/https://www.amazon.com/Tom-Nehmy/e/B07Q5ZNVXC%3Fref=dbs_a_mng_rwt_scns_share JOIN MY COMMUNITY In The Space Between membership, you'll get access to LIVE quarterly Ask Amy Anything meetings (not offered anywhere else!), discounts on courses, special giveaways, and a place to connect with Amy and other like-minded people. You'll also get exclusive access to other behind-the-scenes goodness when you join! Click here to find out more --> https://shorturl.at/vVrwR Stay Connected: - Instagram - https://tinyurl.com/ysvafdwc- Facebook - https://tinyurl.com/yc3z48v9- YouTube - https://tinyurl.com/ywdsc9vt- Website - https://tinyurl.com/ydj949kt Life, Death & the Space Between Dr. Amy RobbinsExploring life, death, consciousness and what it all means. Put your preconceived notions aside as we explore life, death, consciousness and what it all means on Life, Death & the Space Between.**Brought to you by:Dr. Amy Robbins | Host, Executive ProducerPodcastize.net | Audio & Video Production | Hosted on Acast. See acast.com/privacy for more information.

Editor-in-Chief of the Archives of Disease in Childhood, Dr. Nick Brown, and Senior Editor of ADC, Dr. Rachel Agbeko bring you the monthly Atoms - the highlights of the June 2025 issue. Read it on the Archives of Disease in Childhood website: https://adc.bmj.com/content/110/6/i     Please listen to our regular podcasts and subscribe in Apple Podcasts, Google Podcasts, Stitcher and Spotify to get episodes automatically downloaded to your phone and computer. And if you enjoy the podcast, please leave us a review at https://podcasts.apple.com/gb/podcast/adc-podcast/id333278832

This week's conversation with filmmaker Stephen Berkley left me in awe. His documentary Life with Ghosts reveals how his mother's crippling grief transformed when she began communicating with spirits. We explore automatic writing, induced after-death communication therapy (IADC), and why therapists MUST listen to clients' spiritual experiences. As a psychologist and medium, I'm passionate about bridging science and spirituality—especially for those drowning in loss. If you've ever felt a loved one's presence or questioned the afterlife, this episode is your validation. Plus: I'm launching a course for clinicians on spiritually informed therapy! Join me as we tear down the walls between grief and grace.00:00 Film "Life with Ghosts": Grief & the Afterlife 00:54 Podcast Intro & Stephen Berkley Welcome 02:03 Stephen's Mother: Complicated Grief Crisis 04:04 Ethel's Automatic Writing Revelation 06:09 Skepticism vs. Spiritual Connection 12:37 Grief Counselor's Dismissal of ADC 15:46 Scientific Backing: Dr. Dewi Rees Study 21:48 Induced After-Death Communication28:31 Stephen's Personal Spirit Communication Practices 33:40 Mainstreaming ADC: Research & Resistance 39:15 Therapists & Spiritual Openness41:48 Film Impact & PBS Release 44:33 Where to Watch & Closing TEPHEN BERKLEY· Watch Life with Ghosts: lifewithghosts.com· www.grief2growth.com In The Space Between membership, you'll get access to LIVE quarterly Ask Amy Anything meetings (not offered anywhere else!), discounts on courses, special giveaways, and a place to connect with Amy and other like-minded people. You'll also get exclusive access to other behind-the-scenes goodness when you join! Click here to find out more --> https://shorturl.at/vVrwR - Instagram - https://tinyurl.com/ysvafdwc- Facebook - https://tinyurl.com/yc3z48v9- YouTube - https://tinyurl.com/ywdsc9vt- Website - https://tinyurl.com/ydj949kt Life, Death & the Space Between Dr. Amy RobbinsExploring life, death, consciousness and what it all means. Put your preconceived notions aside as we explore life, death, consciousness and what it all mean**Dr. Amy Robbins | HostPodcastize.net | Audio & Video Production | Hosted on Acast. See acast.com/privacy for more information.

Arduino. Founded in Italy twenty years ago by a group of visionary educators and engineers, Arduino was born out of a desire to democratize electronics and make it accessible to everyone. Named after a bar in Ivrea, the platform started with hand-assembled circuit boards for students at the Interaction Design Institute Ivrea (IDII). The founders—Massimo Banzi, David Cuartielles, David Mellis, Tom Igoe, and Gianluca Martino—made key decisions to keep the hardware and software open-source, ensuring that anyone could learn, create, and innovate.   The result is… a world where anyone, regardless of their technical background, can create electronic projects that once seemed out of reach. This is the world that Arduino has made possible.   The significance of Arduino extends far beyond its technical specifications. It has lowered barriers of entry, making electronics affordable and accessible. Its massive open-source community fosters sharing and innovation, sparking the Maker movement and encouraging creation over consumption. Arduino has become a platform, bridging disciplines like art, design, engineering, and computer science, and enabling rapid prototyping. Its impact is felt in education, product development, and the philosophy of technology accessibility.   Arduino has inspired a global movement, empowering hobbyists, students, artists, and professionals to bring their ideas to life. It has influenced modern IoT and smart devices, proving that with the right tools, anyone can be an innovator. Arduino's choice of the AVR ATmega168 and later the ATmega328P microcontrollers was pivotal. These microcontrollers offered a balance of performance, cost, and ease of use, featuring 8-bit architecture, flash memory, SRAM, EEPROM, and built-in peripherals like timers, ADC, PWM, UART, SPI, and I2C. This made them ideal for a wide range of applications, from simple projects to complex prototypes.   What happens next is anybody's guess, but the frontiers spawned by the Shockley's and Moore's of the world, with their advanced educations and access to vast amounts of capital, are giving way to the kid in their bedroom, tinkering with a board and a laptop, intent on building a thing – turning their imagination into reality through simple advancements in integrated circuits, sensors, and open-source software.   How can Microchip Technology fuel the ethos of the Do-It-Yourself Maker movement?

Kara Werner, VP & GM at Tempus AI, joins Kellogg MBA student Ashley Lemon to discuss how Tempus makes patient data meaningful - enabling earlier cancer diagnoses and accessible precision medicine. They also discuss Kara's career journey at the healthtech startup and advice for MBAs looking to break into the space.LinkedInTimestamps:(1:47) Kara's why: from Kellogg to Tempus AI(4:17) Fixing what's broken: structuring and operationalizing multimodal patient data(10:08) Tempus's edge: RNA & DNA, AI-enabled diagnostics platform & strategic partnerships (14:58) AI in action: how Tempus One, Lens & Next connect patients to trials and testing to close care gaps(18:27) Standing up pharma biz: building and adapting for a new client(26:02) What Kara's excited about: tissue-sparing RNA for identifying ADC candidates(28:55) MBA advice: taking Medvec's Negotiations, welcoming challenge, pivoting with purpose(36:24) Wildest & craziest dream: travel experience curator!Visit our podcast page for more episodes on trends and innovation in healthcare and follow our socials so you never miss an update.

Arduino. Founded in Italy twenty years ago by a group of visionary educators and engineers, Arduino was born out of a desire to democratize electronics and make it accessible to everyone. Named after a bar in Ivrea, the platform started with hand-assembled circuit boards for students at the Interaction Design Institute Ivrea (IDII). The founders—Massimo Banzi, David Cuartielles, David Mellis, Tom Igoe, and Gianluca Martino—made key decisions to keep the hardware and software open-source, ensuring that anyone could learn, create, and innovate.   The result is… a world where anyone, regardless of their technical background, can create electronic projects that once seemed out of reach. This is the world that Arduino has made possible.   The significance of Arduino extends far beyond its technical specifications. It has lowered barriers of entry, making electronics affordable and accessible. Its massive open-source community fosters sharing and innovation, sparking the Maker movement and encouraging creation over consumption. Arduino has become a platform, bridging disciplines like art, design, engineering, and computer science, and enabling rapid prototyping. Its impact is felt in education, product development, and the philosophy of technology accessibility.   Arduino has inspired a global movement, empowering hobbyists, students, artists, and professionals to bring their ideas to life. It has influenced modern IoT and smart devices, proving that with the right tools, anyone can be an innovator. Arduino's choice of the AVR ATmega168 and later the ATmega328P microcontrollers was pivotal. These microcontrollers offered a balance of performance, cost, and ease of use, featuring 8-bit architecture, flash memory, SRAM, EEPROM, and built-in peripherals like timers, ADC, PWM, UART, SPI, and I2C. This made them ideal for a wide range of applications, from simple projects to complex prototypes.   What happens next is anybody's guess, but the frontiers spawned by the Shockley's and Moore's of the world, with their advanced educations and access to vast amounts of capital, are giving way to the kid in their bedroom, tinkering with a board and a laptop, intent on building a thing – turning their imagination into reality through simple advancements in integrated circuits, sensors, and open-source software.   How can Microchip Technology fuel the ethos of the Do-It-Yourself Maker movement?

While on site at the 2025 Spring Meeting of the ABA Antitrust Law Section, the Our Curious Amalgam team recorded interviews with senior competition agency enforcers from all over the world, including Germany and Portugal. In the first segment of this episode, James Hunsberger interviews Andreas Mundt, the President of Germany's Federal Cartel Office (Bundeskartellamt) and Chair of the Steering Group of the International Competition Network (ICN). Next, Jeny Maier's speaks with Nuno Cunha Rodrigues, the President of the Portuguese Competition Authority (AdC). Listen to this episode to hear what's been happening in their respective agencies and what makes them happy outside of competition law. With special guests: Andreas Mundt, President, Bundeskartellamt and Nuno Cunha Rodrigues, President, Autoridade da Concorrência Related Links: Federal Cartel Office of Germany (Bundeskartellamt) International Competition Network Portuguese Competition Authority (AdC) Hosted by: Alicia Downey, Downey Law LLC, James Hunsberger, Axinn, Veltrop & Harkrider LLP, and Jeny Maier, Axinn, Veltrop & Harkrider LLP

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Moderna has withdrawn its application for a combination flu and COVID-19 vaccine after discussions with the FDA. The vaccine had shown efficacy in eliciting antibodies, but the company decided to pull the application. In the biotech market, executives from NextGen companies discussed strategies for surviving in what they described as a "moribund" market during a webinar. Biospace's nextgen companies are thriving in a challenging biotech market. Executives discuss survival strategies in the webinar "Are We There Yet?" Pfizer's $6 billion China deal stands out in a competitive market, with Novartis' $4 billion partnership following closely. Biopharma companies are facing pressure to cut assets early due to rising development costs and regulatory hurdles. Lotte Biologics offers specialized end-to-end services at its ADC facility in Syracuse, NY. Other top stories include the FDA's new risk-based approach to COVID-19 vaccines, Genentech's investment in Orionis, and Bio-Rad's new center for excellence for biotherapeutic antibody discovery. Roche's Genentech recently did not win adcomm backing for an expansion. Pfizer has made a deal in China, and RFK claims ignorance about HHS research cuts during a hearing. The top 5 most active corporate VCs in pharma are also highlighted. Additionally, upcoming events and job opportunities in the biotech industry are featured.In conclusion, the biotech market is presenting challenges for companies, but there are opportunities for growth and strategic partnerships. Stay tuned for more updates on regulatory changes, investment deals, and industry trends in the world of Pharma and Biotech. Thank you for listening to Pharma and Biotech daily.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.At a recent U.S. Senate hearing, Health and Human Services Secretary was questioned about cuts being made to the department and his stance on endorsing the measles vaccine during a growing outbreak. The hearing was tense at times, with RFK Jr. firm on supporting the cuts but wavering on his stance on the MMR vaccine. AbbVie's ADC received accelerated approval for lung cancer treatment, FDA delays decision on Biohaven's application, and chaos ensues at the FDA's advisory committee planning office after workforce cuts. Sino Biological offers solutions for autoimmune disease research, with reagents for nearly 50 diseases. Novo Nordisk has invested $2.4 billion in a new oral obesity drug through a deal with Septerna, aiming to catch up with competitors in the oral weight loss space. AbbVie has committed $335 million upfront in a partnership with Adarx Pharmaceuticals for siRNA research, while GSK has abandoned a TIGIT therapy and instead acquired rights to a liver drug from Boston Pharmaceuticals for potential $2 billion deal. This news highlights the ongoing developments and investments in the pharmaceutical industry.

This week's EYE ON NPI is a follow up to one we did a few years ago on the similarly-named BQ25792 (https://blog.adafruit.com/2021/05/06/eye-on-npi-ti-bq25792-i2c-controlled-1-4-cell-5a-buck-boost-battery-charger-eyeonnpi-adafruit-digikey-adafruit-digikey-txinstruments/). The BQ25798 (https://www.digikey.com/short/vnr279pz) builds on the '92 by adding selectable dual inputs and true MPPT solar support. This chip is inexpensive, powerful and can handle almost any battery and power source matching you desire. Let's look at some specifications: High power density, high integration buck-boost charger for 1-4 cell batteries supporting USB PD 3.0 profile – Integrates four switching MOSFETs, BATFET – Integrates input and charging current sensing Highly efficient – 750-kHz or 1.5-MHz switching frequencies – 5-A charging current with 10-mA resolution 96.5% efficient: 16-V battery at 3A from 20V Supports a wide range of input sources Autonomously sampled open circuit voltage (VOC) maximum power point tracking (MPPT) for charging from a photovoltaic panel – 3.6-V to 24-V wide input operating voltage range with 30-V absolute maximum rating – Detects USB BC1.2, HVDCP and non-standard adapters Dual-input power mux controller (optional) Narrow voltage DC (NVDC) power path Backup Mode with Ultra-fast switchover to adjustable voltage Powers USB port from battery (USB OTG) – 2.8-V to 22-V OTG output voltage with 10-mV resolution to support USB-PD PPS – OTG output current regulation up to 3.32 A with 40-mA resolution Flexible autonomous and I2C mode for optimal system performance Integrated 16-bit ADC for voltage, current, and temperature monitoring Like the '92, the BQ25798 (https://www.digikey.com/short/vnr279pz) supports any size battery. We have lots of battery packs in the Adafruit shop, and in particular we use 1S batteries – if there are more batteries, they are wired in series. But there's lot of folks who are building robotics that require higher voltages, so they have 2S, 3S, or 4S batteries. This charger can handle any of 'em, and you can configure the battery pack size using a simple resistor on the PROG port. In this case it also allows the chip to run in 'standalone' mode without the use of I2C to configure. The biggest improvement you get with the BQ25798 (https://www.digikey.com/short/vnr279pz) is true solar MPPT support. The BQ25792 had VINDPM and IINDPM – the ability to track the input voltage to make sure it is not drooping from overdraw. While this lets you get pretty-close-to-MPPT it isn't true power-point-tracking which requires perturbation around the voltage to adjust as light and temperature affect the solar panel's efficiency. The '98 does this 'right' and even has a K Factor adjustment register - you can tweak this to get the best results based on different weather/temperature (https://www.ti.com/video/6287049638001)- or stick to the default value for good results. Another new feature is 'selectable dual-inputs' what this means if you can set up two power inputs - say DC plug and Solar - and then have the chip switch between them. This is particularly useful because you can't just use two OR'ing diodes to select the power source: the solar panel might have a higher initial open-voltage but can't supply as much current as a DC plug. I2C lets you select which one is priority! The BQ25798 (https://www.digikey.com/short/vnr279pz) also has many of the cool features we liked in the BQ25792: On-The-Go mode where you can turn the buck-boost around and have it generate a variable voltage output, say 5V for powering other USB devices. Another thing that works is powering over USB where you can have the BQ negotiate 'high voltage' support from USB 3 ports. Note that this isn't USB Type C power negotiation, for that you'll want to get a separate USB Type C PD negotiation chip like the TPS25750D (https://www.tij.co.jp/jp/lit/ml/slpp103/slpp103.pdf)...we're hoping there's a future version with PD built in! There's also a built in 16-bit ADC that you can use to monitor various voltages and current draw. While you can charge the battery in 'standalone' mode - you really do need I2C to get the best performance and capabilities. Thankfully there's not a huge number of registers, and SDA/SCL can be 3 or 5V logic signals so you should be able to get it working on anything from an ATmega328 to a Raspberry Pi. We like the high integration: you really only need a few passives and an inductor to get a fantastic all-in-one charger for any lithium ion battery pack. If you're intrigued and would like more information, you've come to the right place! DigiKey has the BQ25798 (https://www.digikey.com/short/vnr279pz) in stock right now for immediate shipment. Order today and you can start designing your solar-powered products of the future by tomorrow afternoon.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. The FDA is planning to fully integrate AI into their decision-making process by June 30, with individual centers starting the rollout immediately. Sanofi has cut off its antibody partner, leading to an 80% reduction in headcount at IgM Biosciences. The FDA has faced delays, including missing review dates for GSK's Nucala. President Trump is expected to unveil a drug pricing plan on Monday that has been criticized by big pharma and patient groups. Lotte Biologics offers end-to-end services for ADC manufacturing in Syracuse, NY. Rallybio, Insitro, Shape, and Vor have all downsized their workforces.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novo Nordisk predicts a brighter future for Wegovy with the end of the semaglutide shortage, but analysts remain skeptical as Eli Lilly's Zepbound gains ground in sales. The new HHS vaccine requirement has raised questions about its true intentions, with leading vaccine physician Paul Offit criticizing the lack of clarity. Meanwhile, pharmaceutical imports from Ireland are on the rise, biotech stocks fell after Vinay Prasad was named to succeed Marks at CBER, and Lotte Biologics' ADC facility in Syracuse offers end-to-end services for antibody manufacturing. CRISPR's Casgevy is gaining traction with more gene therapy proof of concept expected in 2025, impacting M&A and IPOs in the biotech industry. Summit Pharmaceuticals is nearing the first global phase III data for Keytruda, set to lose exclusivity in 2028 and potentially face competition from biosimilars. A report suggests that low-price drug nations are benefiting from US innovation, undervaluing innovative medicines by 90%. VC financing in biopharma declined by 20% in Q1, but megarounds kept the median deal size high. M&A and IPOs faced challenges due to policy issues, leading to an increase in licensing deals. Novo vows to improve market access for Wegovy, while Trump orders FDA to ease US plant expansion and increase inspections of foreign facilities. BMS pledges a $40 billion investment in the US, Novartis makes M&A moves, and Lilly remains unfazed by CVS's decision to side with Novo in the obesity market battle. Some drugmakers are stockpiling products in the US amid Trump's trade war. NGM terminates half of its staff as its lead asset moves through a registrational study. Job opportunities in clinical quality assurance audit, RBQM central statistical monitoring, and field medical capabilities are available.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.President Donald Trump has issued an executive order to expedite the timeline for building new facilities in the US while increasing inspections on foreign plants. Despite a drop in venture capital fundraising in the first quarter of the year, large investments are still being made in the pharmaceutical industry. Companies like BMS are investing billions in US manufacturing despite potential tariffs. Vertex has seen success with their non-opioid pain drug launch and biopharma venture capital fundraising has declined, but median deal sizes remain high. Lotte Biologics offers specialized ADC manufacturing services in Syracuse, NY. Other news includes Lilly's ALS pipeline expansion, states suing to block HHS cuts, and layoffs at PTC despite a Phase II win. Thank you for tuning in to today's episode of Pharma and Biotech daily. Let's dive into the latest updates from the industry.

Antibody-drug conjugates (ADCs) are novel therapeutic agents designed to target specific tumor markers with potent anticancer drugs. The Association of Cancer Care Centers (ACCC) is dedicated to providing up-to-date information on ADC treatment management. In this episode, CANCER BUZZ speaks with Nancy Mallett, a patient advocate, to discuss the patient's perspective and experience receiving treatment for gynecologic cancers, particularly with ADCs such as mirvetuximab soravtansine-gynx. “[Providers] giving me the information and allowing us to decide together, instead of just telling me, makes me feel more cared about and that I'm not just a number, I'm a person. They care about what I think, and look at my life and what it can do for me.” – Nancy Mallett   Nancy Mallett Patient Advocate   Resources:  FDA Approval Summary: Mirvetuximab soravtansine-gynx for FRα-positive, Platinum-Resistant Ovarian Cancer - https://bit.ly/4is00nD  Society of Gynecologic Oncology (SGO): Gynecologic Cancer Resources for Patients and Their Families - https://bit.ly/4jpYaoP  ASCO: Antibody-Drug Conjugates in Gynecologic Cancer - https://bit.ly/42GP5k8  Society of Gynecologic Oncology Journal Club: The ABCs of ADCs (Antibody drug Conjugates) - https://bit.ly/42U2962  Antibody-Drug Conjugates in Gynecologic Cancers - https://bit.ly/4cLYECZ    Funder Statement  This program is supported by AbbVie.   

In this episode, hear Lauren Byers, MD and Christine Hann, MD share their insights on the latest data regarding new therapies targeting B7-H3 in small cell lung cancer including: Rationale for targeting B7-H3Overview of the structure of antibody-drug conjugates (ADCs)Results from the phase I/II IDeate-PanTumor01 trial of ifinatamab deruxtecan (I-DXd) in ES-SCLCData from the phase II IDeate-Lung02 trial of 2 different doses of I-DXd in patients with previously treated ES-SCLCAn overview of the ongoing phase III trials IDeate-Lung02 and IDeate-Lung03 of I-DXd in SCLCEarly phase evidence on other novel B7-H3 ADCs including YL201 and HS-20093Program faculty:Lauren Byers, MDProfessor and Thoracic Section ChiefDepartment of Thoracic/Head and Neck Medical OncologyMD Anderson Cancer CenterHouston, TexasChristine L. Hann, MD, PhDAssociate Professor of OncologyDirector, Small Cell Lung Cancer TherapeuticsJohns Hopkins University School of MedicineBaltimore, Maryland

Part 2 of our series dives deeper into the explosion of ADC clinical drug development in China

On the show: Why Trump vetoed Israel's attack on Iran, the latest from Gaza and Yemen and we speak to ADC legal director Chris Godshall-Bennett about protecting rights amid US crackdown.

Featuring a slide presentation and related discussion from Dr Adrienne G Waks, including the following topics: Updated analyses from key studies of the 21-gene Recurrence Score® for localized ER-positive breast cancer (29:30) Four-year landmark analysis of the NATALEE trial of adjuvant ribociclib with nonsteroidal aromatase inhibitor for localized breast cancer (9:49) The PADMA trial of palbociclib with endocrine therapy compared to chemotherapy induction followed by endocrine therapy maintenance for hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (mBC) (11:25) Imlunestrant with or without abemaciclib for metastatic ER-positive mBC (13:18) TROP2-directed antibody-drug conjugates (ADCs) datopotamab deruxtecan and sacituzumab tirumotecan for HR-positive/HER2-negative mBC (17:50) Recent analyses from the DESTINY-Breast06 trial of trastuzumab deruxtecan (T-DXd) after endocrine therapy for HR-positive, HER2-low or HER2-ultralow mBC (21:09) The ICARUS-BREAST01 Phase II trial of the HER3-targeted ADC patritumab deruxtecan for HR-positive/HER2-negative mBC (26:02) Updates from neoadjuvant/adjuvant trials of pembrolizumab (KEYNOTE-522) and atezolizumab (NSABP B-59/GBG 96-GeparDouze) for localized triple-negative breast cancer (TNBC) (27:36) Ten-year update of the OlympiA trial of adjuvant olaparib for patients with germline BRCA1/2-mutated HER2-negative localized breast cancer (31:23) Exploratory analysis of patients who did or did not receive prior PD-1/PD-L1 inhibition in the Phase III OptiTROP-Breast01 study of sacituzumab tirumotecan versus chemotherapy for previously treated advanced TNBC (32:56) CNS efficacy of T-DXd (DESTINY-Breast12 trial) and outcomes with palbociclib combined with anti-HER2 therapy (AFT-38 PATINA trial) for HER2-positive mBC (34:04) CME information and select publications

This week's EYE ON NPI is Pretty Sweet Of Course! It's the Infineon Technologies PSOC Control C3 Microcontroller Line (https://www.digikey.com/short/8cw3wpp8) a souped-up microcontroller that is a perfect choice for engineers who need to do some motor control while also managing buttons, LEDs, displays, and other product requirements all on one chip. With a the high-speed ADCs on board, you can manage your BLDC motors and handle the feedback loop in firmware for dynamic tuning without the expense of a specialized co-processor. The PSOC Control C3 series comes in two flavors, the Entry and Main line chips (https://www.infineon.com/cms/en/product/microcontroller/32-bit-psoc-arm-cortex-microcontroller/32-bit-psoc-control-arm-cortex-m33-mcu/psoc-control-c3m/). Both are based on the Arm Cortex M33 which means you know that your CMSIS-based code will be an easy compile and you can use existing pre-compiled libraries. The M33 line is an upgrade to the M3 and M4, giving you the same or better clock speeds and FPU/DSP commands you get with the M4 plus TrustZone and better power efficiency. The Entry line runs at 100MHz, with max 256k Flash 64K SRAM, 10-bit DAC, a 6 MSPS 12-bit ADC, 16 x 16-bit + 4 x 32-bit TCPWMs and a "CORDIC math coprocessor". The Main line can run at 180MHz, same Flash/SRAM and TCPWMs, and has a 12 MSPS ADC plus 4-channel HRPWM with less than 100ps resolution. Both come in 48 and 64 pin TQFP/QFN varieties, the Main line also has an 80-pin version. (There will also apparently be a Performance line, so far un-announced, which may offer more memory / higher frequency). Both have FPU/DSP support, so you'll be able to process the 6 or 12-MSPS ADC data quickly. And the CORDIC processor (https://en.wikipedia.org/wiki/CORDIC) optimizes trig functions like sin/cos/tan/ln so you don't need lookup tables for performing these floating point calculations. These are particularly useful when handling motor motion calculations since they are often sinusoidal and we need to convert to-and-from the ADC measurements to the precision PWM timers. There's a huge selection of Arm processors out there, but the PSOC Control C3 has the best peripherals for motor control: it's rare to see 12MSPS 12-Bit ADC plus so many 16-bit and 32-bit timers with high-speed PWM. The CORDIC co-processor especially will make managing BLDC or Stepper motors a breeze. Plus you still get all the peripherals you would expect of a microcontroller: I2C, UART, SPI, CAN bus, DAC, IRQs, and lots of GPIO. That means you can handle all the other stuff your product has to do while also managing the motor in the background, saving you lots of space and money in BOM costs and fewer integration woes when trying to communicate between a main processor and a motor-control co-processor. The KITPSC3M5EVK eval board (https://www.digikey.com/en/products/detail/infineon-technologies/KITPSC3M5EVK/25880112) is in stock right now if you want a ready-to-go kit at a good price. It comes with 'Arduino shield compatible" pinouts plus a USB / debug interface, and MikroBus connector for expansion. You can also pick up just the bare chip - for example the PSC3M5FDS2ACQ1AQSA1 (https://www.digikey.com/short/8cw3wpp8) is a fancy version with 256K of flash, the 12 Msps ADC, and hall encoder in a TQFP-64 package. It's in stock now at DigiKey for immediate shipment! Order today and you can have a powerful microcontroller with excellent motor feedback control in your hands by tomorrow morning.

We discuss several legal matters, mostly dealing with how law affects business and how legislators are treating AI. For those who don't know, JAG is a military lawyer, and ADC is a military defense attorney. The WannaPractice app: www.wannapractice.com Use the code “WP50POFF” at registration for 50% off the regular price.The WannaBeA training material: wannabeacissp.comMany thanks to co-host Matt Snoddy! Go buy consulting services from him: http://www.networktherapists.com/You can now sponsor The Sensuous Sounds Of INFOSEC! Buy us a gallon of gas here: https://www.buymeacoffee.com/securityzedVisit our friend and co-host Raphty here: safing.io

For this week's EYE ON NPI, we'll Hazard a guess that you'll be excited to see the Raspberry Pi RP2350 chip available for purchase at Digi-Key for integration into your next design. We've been working with this chip for a few months and it's quickly becoming our favorite Arm Cortex chip, with fun peripherals and a well-supported toolchain. It also is one of the first mass-produced RISC-V chips: one that you can buy and start using for trying out RISC-V development without the 'risc' of worrying you may have picked the wrong core. Available in two chip sizes and with a boost in performance and peripherals, the RP2350 (https://www.digikey.com/short/mzpjhptm) represents a big upgrade to the RP2040 (https://www.digikey.com/en/products/detail/raspberry-pi/SC0914-13/14306010) that you've seen take over the microcontroller world over the last 4 years. Raspberry Pi is famous for their single board computers (https://www.digikey.com/en/products/filter/single-board-computers-sbcs/933) so much so that they created a full market for sub-$100 all-in-one PCs. The big disruption we feel they brought to the market was the creation of a hackable and open-source ecosystem with good main-line OS and driver support. With well-written documentation and up-to-date Linux software, purchasing a Pi meant you got to join in with a community that was having fun, not struggling with compiling out-of-tree kernel modules and closed-source firmware. So in 2021 when they announced the RP2040, folks were interested: could a SBC maker design low power silicon? Turns out, yes! The RP2040 was a fun dual-core 133 MHz Cortex-M0+ processor, with 264K of SRAM, with a satisfying collection of peripherals: USB, ADC, UART/SPI/I2C, PWM, DMA and timers plus the nifty PIO state machine (https://www.raspberrypi.com/news/what-is-pio/). The killer feature, though, was the price: at $1 a chip, and tons of availability with an on-going chip shortage, the RP2040 won our hearts and soldering stations! Three years later, Raspberry Pi is back with a sequel: The RP2350A (https://www.digikey.com/en/products/filter/microcontrollers/685?s=N4IgTCBcDaIE4AcwGYCsAGAgiAugXyA) and RP2350B (https://www.digikey.com/en/products/filter/microcontrollers/685?s=N4IgTCBcDaIE4AcwGYCsAGAQiAugXyA) two variants of an upgrade chip that keeps what was great about the '2040 but with some boosts. First up, the core was upgraded from dual Cortex-M0's to the M33: this means you get an FPU and better low-power performance, plus TrustZone security. The core is spec'd for 150MHz but we've overclocked it to 264MHz without too much complaint. You also have the option to get dual RISC-V cores (https://riscv.org/) instead. SRAM was also bumped: from 264K to 520KB. This is great for running interpreted languages like MicroPython (https://micropython.org/) or CircuitPython (https://circuitpython.org/). Like the original, the RP2350 does not have any built in FLASH memory. Instead, you will need to wire it to a QSPI flash memory chip (https://www.digikey.com/short/80t4zt5t). This way you can pick from 1 MBytes to 16 MBytes whatever your code size needs. This new chip adds the ability to wire in PSRAM (https://www.digikey.com/short/d8033bfw) to the same QSPI bus plus an extra chip select. This is not going to be nearly as fast as on-chip SRAM, but it's great when you want large working memory that the chip will manage for you: by configuring it in the CMakefile, you 'magically' get a huge area you can malloc. Another improvement is in the number of PIO blocks: the original had 2, the RP2350 has 3. The two biggest new features we found are the new HSTX peripheral and the 80-QFN RP2350B (https://www.digikey.com/en/products/filter/microcontrollers/685?s=N4IgTCBcDaIE4AcwGYCsAGAQiAugXyA) variant. HSTX stands for High Speed Transmission and its a high-speed peripheral that can drive 8 output lines - note that it's output only! There's a few possible use cases, but the core reasoning is that this lets you control a DVI display directly from the chip using just the DMA and internal memory without requiring overclocking, PIO, or an extra core. Note that the built in SRAM limits the size of the display if you want to have a video buffer: you can do 320x240 @16bpp or 640x480 @8bpp but, still! Second, if you found the original QFN-60 a bit constraining in terms of GPIO, the QFN-80 'B' version has 20 extra GPIO available for just 10 cents more. If you've been doing grabby-hands in hopes of getting a reel of RP2350 chips into your next design: today is your lucky day! Digi-Key has these chips in stock RIGHT NOW for immediate shipment. You can get a reel of either A or B type chips, with cut tape individual components coming shortly. Both types are great, but recently we've been having a lot of fun with the roomy B type (https://www.digikey.com/short/mzpjhptm), with the extra GPIO. Order today and you can start integrating the trendiest new silicon into your new PCB assembly by tomorrow afternoon.

Alex Moss and guest co-host Andrew Sinclair are back with a new episode! The boys start off the show with a look back at the latest Players Championship double header from earlier this week, and discuss the significance of titles for Gary Anderson and Martin Schindler. Adam Lipscombe (17:40) is back on the show to reflect on his run to a first ProTour final in Players Championship 7 on Monday. The new PDC tour card holder looks back on his first two months playing on the PDC tour, that eye-catching run to his maiden final this week, as well as explain why he played the World Masters in a Ralph Lauren polo shirt! Alex and Andrew continue their look back at this week's ProTour action in Germany, picking out which other players caught their eye this week, before also delving into the latest Challenge Tour weekend of events and discuss who is the player to beat now after Darius Labanauskas won a pair of titles to replace Beau Greaves at the top of the Order of Merit. Paul Nicholson (56:05) returns to the show ahead of commentating on the European Darts Trophy this weekend. The former major champion talks all things darts including Luke Littler, Beau Greaves, the MODUS Super Series, trying his hand as a presenter, his own playing future, and whether Mark Walsh could make an appearance on our 400th episode! The boys sign off the show with our Question of the Week sponsored by Condor Darts and then Andrew gives his take on the ADC's recent Global Championship announcement and where it leaves the WDF. Enter The Magnificent 8 - Darts Corner's FREE to enter Premier League Predictor for a chance to win the £1,000 jackpot! Join the Darts Strava King group on Strava *** This podcast is brought to you in association with Darts Corner - the number one online darts retailer! Darts Corner offers the widest selection of darts products from over 30 different manufacturers.  Check out Darts Corner here: UK site US site Netherlands site Check out Condor Darts here: UK site *** The Weekly Dartscast is excited to announce it has agreed a new sponsorship deal with kwiff. A growing name in the sports betting sector, kwiff was an official sponsor of the 2023 WDF Lakeside World Championships and has also worked with several other big names in the darts industry. Set up an account and enjoy a flutter on the darts by opening an account on the kwiff website or via their app (iOS / Android). 18+. Terms and conditions apply. Begambleaware.org – please gamble responsibly. *** Sponsorship available! Want your business advertised on the show? Email weeklydartscast@gmail.com for more details and a free copy of our new sponsor brochure! *** Enjoy our podcast? Make a one-off donation on our new Ko-Fi page here: ko-fi.com/weeklydartscast Support us on Patreon from just $2(+VAT): patreon.com/WeeklyDartscast Thank you to our Patreon members: Phil Moss, Gordon Skinner, Connor Ellis, Dan Hutchinson

Pasqual Gutierrez is a writer, director and actor. Sundance 2025 Comedy “Serious People” was his debut into feature filmmaking alongside veteran documentary filmmaker Ben Mullinkosson who co-wrote and directed. Gutierrez is also 1/2 of music video directing duo CLIQUA who has worked with some of the biggest names in the industry including The Weeknd, Bad Bunny, J Balvin, Rosalia, Madonna, and more. Gutierrez is developing his second feature, a sequel to Serious People. Ben Mullinkosson was raised in the suburbs of Chicago and trained in directing at Chapman University. After graduating Ben spent 15 years directing commercial work and documentary films between Los Angeles and Shanghai. Ben's newest film, SERIOUS PEOPLE, directed with Pasqual Gutierrez premiered at Sundance 2025 Film Festival. The film is sold by 2AM. He is most well known for his feature length film DON'T BE A DICK ABOUT IT which won the Audience Award at the International Documentary Film Festival of Amsterdam in 2018 and is currently distributed in North America by Oscilloscope Laboratories. en also recently premiered his five-year project, THE LAST YEAR OF DARKNESS, which won the Special Jury Mention prize at CPH:DOX in March 2023 and was sold to MUBI. The film was represented for sales by CAA and a is co-production between Kindred Spirit (Executive producer of THE FAREWELL and HONEY BOY) and /avelength (Executive producer of CUSP and WON'T YOU BE MY NEIGHBOR). Among Ben's advertisements, SAMSUNG: VOICES OF LIFE with Agency Leo Burnett won a silver lion at the Cannes Lions Advertising Festival in 2016. His UNESCO World Heritage Ad with agency TBWA, THE LEFT HAND, was nominated for the ADC awards in 2020. His other clients include Facebook, Beats, Vivo, Yelp, The Home Depot, VANS, Converse, Apple, Red Bull, VICE and Nowness. His short film, GNARLY IN PINK, premiered at Tribeca Film Festival in 2013 and premiered online as a NYT Op-Doc. A number of his other short films have received Vimeo Staff Picks and others have millions of views. Ben is repped for commercials by Florence in Los Angeles. He also speaks Chinese fluently and is an X Games gold medalist for halfpipe skateboard competition in China.  Topics Discussed In This Episode: How the idea for Serious People came to Pasqual in a dream (00:03:15) Pasqual and Ben's writing process for Serious People (00:08:26) Developing the film's narrative and structure (00:11:38) Casting Miguel Huerta as the doppelgänger (00:16:17) Pasqual's reflections on parenting (00:23:46) Friendship, the creative process, and working with friends (00:29:23) Being authentic and leaning into one's childlike sensibilities (00:45:32) Shifting our perspective and opening ourselves up for magic to be observed (00:59:36) Final thoughts and future plans (01:09:26) artistdecoded.com Ben's Links: benmullinkosson.com instagram.com/benmullinkosson Pasqual's Links: pasqualgutierrez.com instagram.com/pasqualgutierrez instagram.com/cliquamundo